A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-05-24
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3127804
given as monotherapy and in combination with Ramucirumab for participants with advanced or
metastatic solid tumors. The study will also include a safety exploration for the combination
of LY3127804 plus ramucirumab and paclitaxel